Said M Sebti

This inventor holds 109 USPTO granted patents and 19 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Cancer Treatment (CPC class A61K31-7064). Top assignees: University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Inc., Yale University. Active years: 1995-2024.

USPTO Granted Patents = 109 (Patent Applications = 19)

% Patents Active = 61.5

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 5)

Average Co-Inventor Count = 2.6

ph-index = 8

Forward Citations = 265(Granted Patents)

Forward Citations (Not Self Cited) = 224(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Pittsburgh, PA (US) (1995 - 2000)
Tampa, FL (US) (1998 - 2024)

Company Filing History:

66 out of 1,986

University of South Florida

patents

39 out of 312

H. Lee Moffitt Cancer Center and Research Institute, Inc.

University of Pittsburgh

patents

5. 8 out of 1,370

University of Central Florida Research Foundation Inc.

patents

6. 3 out of 45

Torrey Pines Institute for Molecular Studies

patents

7. 2 out of 3

Chongqing Zein Pharmaceutical Co., Ltd

patents

8. 2 out of 957

The United States Government as Represented by the Department of Veterans Affairs

University of Florida Research Foundation Inc.

patents

11. 2 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2024

Loading Chart...

Areas of Expertise:

STAT3 Inhibitors

KRAS Inhibitors

Aurora Kinase

Graft Versus Host Disease

Geranylgeranyltransferase I

Platinum Compounds

Breast Cancer

Proteasome Inhibitors

Rho Kinase

Cell Cycle Arrest

Granulocyte Colony-Stimulating Factor

Tumor Regression

109 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12060332 - Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease (2024-08-13),

2. 11583525 - Geranylgeranyltransferase I inhibitor for treatment of a PTEN defective cancer (2023-02-21),

3. 11571418 - Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells (2023-02-07),

4. 11352370 - Mutant KRAS inhibitors (2022-06-07),

5. 11203576 - Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease (2021-12-21),

6. 10954258 - STAT3 dimerization inhibitors (2021-03-23),

7. 10946012 - Methods for inducing tumor regression, inhibiting tumor growth, and inducing apoptosis in breast tumors with geranylgeranyltransferase I inhibitors (2021-03-16),

8. 10813927 - Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells (2020-10-27),

9. 10813913 - Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF) (2020-10-27),

10. 10806712 - Small molecule inhibitors of STAT3 with anti-tumor activity (2020-10-20),

11. 10780104 - Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof (2020-09-22),

12. 10744148 - Methods of treating breast cancer that overexpress AKT kinase (2020-08-18),

13. 10711014 - Mutant KRas inhibitors (2020-07-14),

14. 10662180 - Proteasome chymotrypsin-like inhibition using PI-1833 analogs (2020-05-26),

15. 10507228 - Methods and compositions related to KRAS inhibitors (2019-12-17),

Title: The Innovative Journey of Inventor Said M Sebti

Introduction: Said M Sebti, a talented inventor based in Tampa, FL, has made significant contributions to the field of innovation with his groundbreaking ideas and inventions.

Latest Patents: Said M Sebti holds several patents in various technological fields, showcasing his diverse range of expertise and creativity in inventing new solutions to complex problems.

Career Highlights: Throughout his illustrious career, Said M Sebti has demonstrated a keen ability to transform innovative ideas into tangible inventions that have the potential to revolutionize industries and improve people's lives.

Collaborations: Said M Sebti has collaborated with leading research institutions, universities, and companies to further develop his inventions and bring them to the market, highlighting his commitment to advancing technology through partnerships and collaborations.

Conclusion: In conclusion, Said M Sebti's passion for innovation, coupled with his dedication to turning ideas into reality, solidifies his position as a prominent inventor in the vibrant city of Tampa, FL. His relentless pursuit of excellence continues to inspire the next generation of inventors and innovators.